Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Two-Part, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS) Undergoing Endovascular Thrombectomy (EVT)

NCT05198323 is registered in ClinicalTrials.gov with Lumosa Therapeutics Co., Ltd. as lead sponsor.

NCT NCT05198323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05198323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Two-Part, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS) Undergoing Endovascular Thrombectomy (EVT)
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 11, 2022
Completion date
December 31, 2026
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke